What GLP-1 Clinical Trial Evidence Actually Shows

A fair reading of what the major published GLP-1 trials measured, who was studied, and what the average results do and do not promise any single patient.

The major GLP-1 clinical trial evidence shows that, on average, adults taking the highest studied doses of semaglutide or tirzepatide alongside lifestyle support lost a meaningful percentage of their starting body weight over roughly a year or more, with tirzepatide trials generally reporting larger average reductions than semaglutide trials. These are group averages from controlled studies, not promises to any one person. Individual results vary widely.

What did the largest semaglutide and tirzepatide trials actually measure?

When people quote a GLP-1 number, they are usually quoting the primary endpoint of a randomized trial: the average percent change in body weight from the start of the study to a fixed time point, compared against a placebo group. That is the figure the studies were built to measure. The semaglutide weight-management program and the tirzepatide weight-management program each enrolled large groups, randomized them to drug or placebo, and tracked the difference over months.

A few things matter about that design. The headline result is a mean, which means some participants did far better than the average and some did far worse. The number reflects the highest doses studied, reached after a slow titration, not a starting dose. And the comparison is against placebo, so part of what you are reading is the gap between the drug arm and people who received supportive care without the active medication.

Semaglutide is the active ingredient in Ozempic and Wegovy, which are products of Novo Nordisk. Tirzepatide is the active ingredient in Mounjaro and Zepbound, which are products of Eli Lilly. New Hope Weight Loss is not affiliated with either company. I mention ownership plainly because when patients read a "trial number," they are almost always reading a result that came from one of these branded, FDA-reviewed products under tightly controlled conditions.

Who was actually enrolled, and why does that change the headline?

This is the part most marketing leaves out, and it is the part I spend the most time on with new patients. Trial participants are not a random slice of everyone. They had to meet weight or BMI thresholds, often had specific health profiles, agreed to regular study visits, and met the study's inclusion and exclusion rules. People with certain conditions were screened out. That selection shapes the average you eventually read about.

The other quiet detail is the support given alongside the drug. In the registration trials, participants did not just receive a prescription and disappear. They got structured lifestyle counseling, guidance on reduced-calorie eating, encouragement toward physical activity, and frequent contact with study staff. The published number is the result of the medication plus that scaffolding. When a patient at home reads the same figure but has none of the surrounding support, the comparison is no longer apples to apples.

So the honest way to read a trial average is: this is what a screened, supported, closely monitored group achieved on the studied product at the studied dose. It is a strong signal that the medication works. It is not a forecast for one specific body sitting in front of me.

Is compounded medication the same as the trial drug?

No, and this distinction deserves care. The published trials studied the branded products. Compounded semaglutide and compounded tirzepatide are prepared by pharmacies and are not FDA-approved and not identical to the brand versions. They were not the products tested in those large studies. Anyone applying a brand trial's average to a compounded preparation is borrowing data that was never collected on that exact formulation.

That does not make compounded options useless or wrong to discuss. It means the evidence label has to be accurate. When I talk with patients about a compounded route, I am clear that we are reasoning from the known behavior of the active ingredient, not from a trial that tested the specific compounded product. Results vary by individual, and the data we lean on came from the brand programs. Keeping that line bright is part of being honest with people about what we know and what we are inferring.

How do you read a result responsibly?

Three habits help. First, watch whether a figure is given as percent of body weight or as pounds. Percent is how the trials report, and percent travels better across different starting weights. A pound figure sounds concrete but quietly assumes a particular starting weight, so a "lost X pounds" headline can mislead a person who weighs more or less than the implied average.

Second, ask whether a number describes completers or the full randomized group. "Completers" counts only the people who stayed on the drug to the end. Intention-to-treat counts everyone who started, including those who stopped early for side effects, life, or any reason. Completer numbers usually look better. Both are legitimate, but they answer different questions, and a best-case completer figure is not what a typical starting patient should expect.

Third, remember that an average hides a range. Behind every clean headline sits a spread of outcomes. Some people respond strongly. Some respond modestly. A few barely respond and we change course. Reading the average as if it were everyone's destiny is the single most common mistake I see.

What do trial averages look like in real practice?

In my clinic, the patients who track closest to the published averages tend to be the ones who got the full picture early: a realistic dose timeline, a plan for the weeks when appetite changes feel strange, and steady follow-up. The ones who struggle most are often the ones who arrived expecting the headline number to be a guarantee and felt like they were failing when their body chose a slower path.

So I counsel a range, not a point. I tell people that a good outcome lives inside a band, that the first weeks are about tolerating the medication rather than chasing the scale, and that we will adjust based on how they actually respond. That framing matches the data better than any single figure, and it tends to keep people in treatment long enough to find out where on the curve they land.

Why a single best-case number is the wrong thing to advertise

There is a habit, in some corners of this field, of putting forward one impressive figure as if it were the standard result. I want to correct the practice rather than point at anyone who uses it. A best-case number, stripped of its population, its dose, its support structure, and its range, stops being evidence and starts being a sales line. It sets patients up to feel disappointed by an outcome that the trials would actually call a success.

The fairer standard is simple. Quote the average as an average. Name the dose and the population. Say plainly that results vary by individual. Distinguish brand trial data from compounded preparations. When the field reads the data this way, patients make better decisions, peers trust the conversation, and nobody has to be the cautionary tale. That is the version of evidence review I try to practice, and the version I think the data has earned.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.